JMD TIDES - Oligonucleotide and Peptide - May 18-21, 2008, Las Vegas, NV
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Backus, J.
Right arrow Articles by Verbanac, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Backus, J.
Right arrow Articles by Verbanac, K. M.
JMD 2005, Vol. 7, No. 3
Copyright © 2005 American Society for Investigative Pathology & Association for Molecular Pathology

Identification and Characterization of Optimal Gene Expression Markers for Detection of Breast Cancer Metastasis

John Backus*, Todd Laughlin*, Yixin Wang*, Robert Belly*, Robert White*, Jon Baden*, C. Justus Min{dagger}, Ann Mannie{dagger}, Lorraine Tafra{ddagger}, David Atkins* and Kathryn M. Verbanac{dagger}

From Veridex LLC, * Warren, New Jersey; the Brody School of Medicine, {dagger} East Carolina University, Greenville, North Carolina; and the Anne Arundel Medical Center, {ddagger} Annapolis, Maryland

Sentinel lymph node (SLN) status is highly predictive of overall axillary lymph node involvement in breast cancer. Historically, SLN-positive patients have undergone axillary lymph node dissection in a second surgery. Intraoperative SLN analysis could reduce the cost and complications of a second surgery; however, existing histopathological methods lack standardization and exhibit poor sensitivity. Rapid molecular methods may lead to improved intraoperative diagnosis of SLN metastasis. In this study, we used a genome-wide gene expression analysis of breast and other tissues to identify seven putative markers for detecting breast cancer metastasis. We assessed the utility of these markers for identifying clinically actionable metastases in lymph nodes through reverse transcriptase-polymerase chain reaction analysis of SLNs from 254 breast cancer patients. Polymerase chain reaction signals were compared to pathology on a per-patient basis. The optimal two-gene combination, mammaglobin and cytokeratin 19, detected clinically actionable metastasis in breast SLNs with 90% sensitivity and 94% specificity. Application of stringent criteria for identifying presumptive hematoxylin- and eosin-positive samples increased sensitivity and specificity to 91 and 97%, respectively. This study represents the first comprehensive demonstration of the utility of gene expression markers for detecting clinically actionable breast metastases. An intraoperative molecular assay using these markers has the potential to significantly reduce second surgeries for patients undergoing SLN dissection.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Tsujimoto, K. Nakabayashi, K. Yoshidome, T. Kaneko, T. Iwase, F. Akiyama, Y. Kato, H. Tsuda, S. Ueda, K. Sato, et al.
One-step Nucleic Acid Amplification for Intraoperative Detection of Lymph Node Metastasis in Breast Cancer Patients
Clin. Cancer Res., August 15, 2007; 13(16): 4807 - 4816.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
D. Talantov, J. Baden, T. Jatkoe, K. Hahn, J. Yu, Y. Rajpurohit, Y. Jiang, C. Choi, J. S. Ross, D. Atkins, et al.
A Quantitative Reverse Transcriptase-Polymerase Chain Reaction Assay to Identify Metastatic Carcinoma Tissue of Origin
J. Mol. Diagn., July 1, 2006; 8(3): 320 - 329.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology and the Association for Molecular Pathology.